Oncimmune (ONC) Posts Earnings Results

Oncimmune (LON:ONC) posted its quarterly earnings data on Tuesday. The company reported GBX (5.70) (($0.08)) EPS for the quarter, Bloomberg Earnings reports. The company had revenue of GBX 800 million during the quarter. Oncimmune had a negative return on equity of 81.75% and a negative net margin of 2,521.78%.

Oncimmune (LON:ONC) opened at GBX 142 ($1.96) on Tuesday. Oncimmune has a 12 month low of GBX 100 ($1.38) and a 12 month high of GBX 150 ($2.07). The stock has a market capitalization of $86.07 and a P/E ratio of -1,420.00.

Separately, Berenberg Bank initiated coverage on Oncimmune in a research note on Friday, January 19th. They issued a “buy” rating and a GBX 169 ($2.33) price target on the stock.

WARNING: This article was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/02/13/oncimmune-onc-posts-earnings-results.html.

Oncimmune Company Profile

Oncimmune Holdings Plc is a cancer diagnosis company. The Company is engaged in developing and commercializing its EarlyCDT platform technology. Its geographical segments include United Kingdom, North America and Rest of the world. It is engaged in the development of autoantibody tests that can be applied to a range of solid tumor types.

Receive News & Ratings for Oncimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncimmune and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply